Ran Wei

TL;DR: In the monarchE trial as discussed by the authors , an open-label, randomised, phase 3 trial, adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive early breast cancer at a high risk of recurrence with an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 603 sites including hospitals and academic and community centres in 38 countries.

TL;DR: Abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone as discussed by the authors .

TL;DR: 5-year efficacy results from a prespecified overall survival (OS) interim analysis show abemaciclib plus ET continued to reduce the risk of developing invasive and distant disease recurrence beyond the completion of treatment and further supports the use of abemaciclib in patients with high-risk EBC.

TL;DR: The results of this analysis of the monarchE randomized clinical trial found that treatment with adjuvant abemaciclib plus endocrine therapy demonstrated benefit for patients with hormone receptor–positive, ERBB2−, node-positive, and high-risk early breast cancer who received neoadjuvant chemotherapy before trial enrollment.